Spur typically deploys capital across 15 -18 early stage venture managers over 3 to 4 vintage years, along with select direct investments into companies back by our venture managers.. Our funds invest primarily in US based venture relationships and historically have committed roughly 70% of capital to technology focused investments and 30% to life sciences.
By our conservative estimates, there are roughly 300,000 employees across active portfolio companies – and we believe that the commercialization of innovation leads to wage growth as well as a reliably higher quality of life.
Although Spur has only funded 3% of all life science venture funds, our portfolio companies have brought a remarkable 119 FDA-approved drugs to market since 2007.
